Efficacy of intravitreal bevacizumab for zone‐<scp>II</scp> retinopathy of prematurity

Karkhaneh, Reza; Khodabande, Alireza; Riazi-Eafahani, Mohammad; Roohipoor, Ramak; Ghassemi, Fariba; Imani, Mehdi; Farahani, Afsar Dastjani; Adib, Nazanin Ebrahimi; Torabi, Hamidreza

doi:10.1111/aos.13008

Cited by 49 publications

(40 citation statements)

References 16 publications

(23 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…(Tolentino, 2011) An increasing number of case series of either bevacizumab or ranibizumab treatment, usually in combination with laser but sometimes as monotherapy, have been reported (Micieli et al, 2009, Wallace and Wu, 2013, Mititelu et al, 2012. There have now been (Autrata et al, 2012, Karkhaneh et al, 2016, Kong et al, 2015b, Mintz-Hittner et al, 2011, Moran et al, 2014 five randomized trials of anti-VEGF agents as treatment for ROP published (Autrata et al, 2012, Karkhaneh et al, 2016, Kong et al, 2015b, Mintz-Hittner et al, 2011, Moran et al, 2014.These trials have small numbers of patients and several have design flaws. They cannot at this point be viewed as providing conclusive data on the ocular and systemic outcomes of the premature infants treated.…”

Section: Accepted Manuscriptmentioning

confidence: 99%

“…The primary outcome was serum free VEGF and IGF-1 concentrations to 90 days. Karkhaneh and colleagues (2016), in a study from Iran, enrolled 79 infants with zone II, stage 2 or 3 plus ROP (Karkhaneh et al, 2016). The details of randomisation are uncertain and the primary outcome was treatment failure by 90 weeks PMA; this occurring in 9/43 treated with bevacizumab and 1/36 treated with laser (Karkhaneh et al, 2016).…”

Section: Beat-rop Studymentioning

confidence: 99%

“…Karkhaneh and colleagues (2016), in a study from Iran, enrolled 79 infants with zone II, stage 2 or 3 plus ROP (Karkhaneh et al, 2016). The details of randomisation are uncertain and the primary outcome was treatment failure by 90 weeks PMA; this occurring in 9/43 treated with bevacizumab and 1/36 treated with laser (Karkhaneh et al, 2016). The heterogeneous nature of these studies, generally small sample size and lack of details of the study design mean they add little to our understanding of relative advantages of bevacizumab compared to laser with the clear exception of Lepore (2014) (Lepore et al, 2014).…”

Section: Beat-rop Studymentioning

confidence: 99%

See 2 more Smart Citations

Pathophysiology, screening and treatment of ROP: A multi-disciplinary perspective

Chan‐Ling

Gole

Quinn

et al. 2018

Progress in Retinal and Eye Research

126

107

View full text Add to dashboard Cite

The population of infants at risk for retinopathy of prematurity (ROP) varies by world region; in countries with well developed neonatal intensive care services, the highest risk infants are those born at less than 28 weeks gestational age (GA) and less than 1 kg at birth, while, in regions where many aspects of neonatal intensive and ophthalmological care are not routinely available, more mature infants up to 2000 g at birth and 37 weeks GA are also at risk for severe ROP. Treatment options for both groups of patients include standard retinal laser photocoagulation or, more recently, intravitreal anti-VEGF drugs. In addition to detection and treatment of ROP, this review highlights new opportunities created by telemedicine, where screening and diagnosis of ROP in remote locations can be undertaken by non-ophthalmologists using digital fundus cameras. The ophthalmological care of the ROP infant is undertaken in the wider context of neonatal care and general wellbeing of the infant. Because of this context, this review takes a multi-disciplinary perspective with contributions from retinal vascular biologists, pediatric ophthalmologists, an epidemiologist and a neonatologist. This review highlights the latest insights regarding cellular and molecular mechanisms in the formation of the retinal vasculature in the human infant, pathogenesis of ROP, detection and treatment of severe ROP, the risks and benefits of anti-VEGF therapy, the identification of new therapies over the horizon, and the optimal neonatal care regimen for best ROP outcomes, and the benefits and pitfalls of telemedicine in the remote screening and diagnosis of ROP, all of which have the potential to improve ROP outcomes.

show abstract

Section: Accepted Manuscriptmentioning

confidence: 99%

Section: Beat-rop Studymentioning

confidence: 99%

Section: Beat-rop Studymentioning

confidence: 99%

See 1 more Smart Citation

Pathophysiology, screening and treatment of ROP: A multi-disciplinary perspective

Chan‐Ling

Gole

Quinn

et al. 2018

Progress in Retinal and Eye Research

126

107

View full text Add to dashboard Cite

show abstract

“…Fortunately, the scarring has little impact on the peripheral visual fields in the children (Cryotherapy for Retinopathy of Prematurity Cooperative Group, 2001; Fielder et al, 2015; Harvey et al, 1997; Holm et al, 2015; Larsson et al, 2004; Quinn et al, 2011). Treatment by injection of an antibody against vascular endothelial growth factor (VEGF), which can also cause the abnormal vasculature to resolve, is coming into use; this treatment does not produce peripheral scars (Arambulo et al, 2015; Cayabyab and Ramanathan, 2016; Jefferies, 2016; Karkhaneh et al, 2016; Mintz-Hittner et al, 2016; Quinn and Darlow, 2016). Interestingly, the occurrence of significant ametropia appears to be lower in anti-VEGF treated eyes (Chen et al, 2014; Geloneck et al, 2014).…”

Section: Introductionmentioning

confidence: 99%

The neural retina in retinopathy of prematurity

Hansen

Moskowitz

Akula

et al. 2017

Progress in Retinal and Eye Research

View full text Add to dashboard Cite

Retinopathy of prematurity (ROP) is a neurovascular disease that affects prematurely born infants and is known to have significant long term effects on vision. We conducted the studies described herein not only to learn more about vision but also about the pathogenesis of ROP. The coincidence of ROP onset and rapid developmental elongation of the rod photoreceptor outer segments motivated us to consider the role of the rods in this disease. We used noninvasive electroretinographic (ERG), psychophysical, and retinal imaging procedures to study the function and structure of the neurosensory retina. Rod photoreceptor and post-receptor responses are significantly altered years after the preterm days during which ROP is an active disease. The alterations include persistent rod dysfunction, and evidence of compensatory remodeling of the post-receptor retina is found in ERG responses to full-field stimuli and in psychophysical thresholds that probe small retinal regions. In the central retina, both Mild and Severe ROP delay maturation of parafoveal scotopic thresholds and are associated with attenuation of cone mediated multifocal ERG responses, significant thickening of post-receptor retinal laminae, and dysmorphic cone photoreceptors. These results have implications for vision and control of eye growth and refractive development and suggest future research directions. These results also lead to a proposal for noninvasive management using light that may add to the currently invasive therapeutic armamentarium against ROP.

show abstract

“…Karkhaneh et al [23] reported that there were remaining avascular areas in the peripheral retina of 45% of the infants at 90 weeks postmenstrual age after IVB treatment and 10.5% of the infants who received retreatment. On the other hand, Han et al [24] applied two different doses (0.25 and 0.625 mg) of bevacizumab for treatment of ROP, and they found that nearly full vascularization might be achieved without recurrence or additional treatment.…”

Section: Discussionmentioning

confidence: 99%

The Process of Retinal Vascularization after Anti-VEGF Treatment in Retinopathy of Prematurity: A Comparison Study between Ranibizumab and Bevacizumab

Sukgen

Çömez²,

Koçluk³

et al. 2016

Ophthalmologica

View full text Add to dashboard Cite

Purpose: To compare the effects on the process of retinal vascularization of intravitreal ranibizumab (IVR) and intravitreal bevacizumab (IVB) in the treatment of severe retinopathy of prematurity. Methods: The present study is a bi-centered retrospective study. While 44 eyes of 22 patients in group 1 were applied 0.625 mg bevacizumab, 46 eyes of 23 patients in group 2 were applied 0.25 mg ranibizumab. Retinal vascularization was evaluated clinically. Results: The mean time for completion of vascularization was found to be postmenstrual 55.93 ± 4.13 weeks in group 1 and 56.30 ± 4.30 weeks in group 2. There were signiﬁcant differences in the recurrence prevalence between the two groups. The prevalence of recurrence was found to be significantly higher in the ranibizumab group than in the bevacizumab group (p = 0.023). Conclusions: The study showed that after IVR or IVB treatment, vascularization could be completed with delay; there were no differences in this delay time between the ranibizumab and bevacizumab groups. Besides, avascular areas may remain in the peripheral retina, and additional treatment may be necessary after IVB or IVR treatment. When the treatment was applied as monotherapy, more recurrence was observed in the ranibizumab group.

show abstract

Efficacy of intravitreal bevacizumab for zone‐II retinopathy of prematurity

Abstract: Recurrence of neovascularization with bevacizumab monotherapy seems to be higher than that with conventional laser therapy among infants with Type 1 ROP in zone II ROP but reinjection of bevacizumab causes regression in most recurrent cases.

Cited by 49 publications

References 16 publications

Pathophysiology, screening and treatment of ROP: A multi-disciplinary perspective

Pathophysiology, screening and treatment of ROP: A multi-disciplinary perspective

The neural retina in retinopathy of prematurity

The Process of Retinal Vascularization after Anti-VEGF Treatment in Retinopathy of Prematurity: A Comparison Study between Ranibizumab and Bevacizumab

Contact Info

Product

Resources

About